NeoCOAST-2 trial shows datopotamab deruxtecan clears ctDNA best in lung cancer
Researchers report results from the NeoCOAST-2 phase 2 trial testing new perioperative treatments for resectable non-small cell lung cancer patients.
Treatment arms compared for response rates
The study combined standard chemotherapy with durvalumab and added either oleclumab, monalizumab, or datopotamab deruxtecan. Pathological complete response rates reached 20.3 percent for the oleclumab group, 25.7 percent for monalizumab, and 35.2 percent for the datopotamab deruxtecan arm.
Event-free survival outcomes across groups
Event-free survival rates at twenty-four months were 70.5 percent, 75.7 percent, and 77.9 percent respectively for the three treatment arms. Clearing circulating tumour DNA correlated with longer event-free survival compared to patients who did not clear their ctDNA.
ctDNA clearance linked to better outcomes
Patients showing both ctDNA clearance and pathological complete response experienced the most favourable event-free survival results. The datopotamab deruxtecan combination produced the highest rates of ctDNA clearance among all tested groups.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.